**TEST MENU**

**POLYMERASE CHAIN REACTION (PCR)**

**BORRELIA SPECIES PCR**
DNA detection of Borrelia species by PCR in whole blood, cerebral spinal fluid or synovial fluid. If Borrelia species DNA is detected, then PCR is performed for the identification of B. miyamotoi and B. burgdorferi DNA.

**BABESIA DUNCANI PCR**
DNA detection of B. duncani in whole blood specimens.

**BABESIA MICROTI PCR**
DNA detection of B. microti in whole blood specimens.

**ANAPLASMA PHAGOCYTOPHILUM PCR**
DNA detection of A. phagocytophilum in whole blood specimens.

**EHRlichia Chaffeensis PCR**
DNA detection of E. chaffeensis in whole blood specimens.

**EHRlichia Species PCR**
DNA detection of Ehrlichia species by PCR in whole blood. If Ehrlichia species DNA is detected, then PCR is performed for the identification of E. chaffeensis, E. ewingii, and E. muris eauclairensis DNA.

**SEROLOGY**

**LYME ANTIBODY ANALYSIS (B. burgdorferi)**
Serum, plasma and synovial fluid specimens are tested by Lyme antibody capture (IgM, IgA and IgG) EIA and two IgG Western blots* for detection of antibodies to B. burgdorferi.

**LYME WESTERN BLOT (IgG)**
Serum, plasma and synovial fluid specimens are tested by two IgG Western blots* for detection of antibodies to B. burgdorferi.

**LYME WESTERN BLOT (IgM)**
Serum or plasma specimens are tested by IgM Western blot B. burgdorferi strain G39/40) for detection of antibodies to B. burgdorferi.

**LYME WESTERN BLOT ANALYSIS (IgM + IgG)**
IgM and IgG Western blots (B. burgdorferi strain G39/40)

**LYME CSF AND SERUM RATIO ANALYSIS**
Cerebral spinal fluid (CSF) and serum specimens must be drawn on the same date and are tested by antibody capture (IgM, IgA and IgG) EIA for detection of antibodies to B. burgdorferi. Results include a CSF: serum antibody ratio for each antibody isotype and two IgG Western blots* on serum specimens.

**LYME ANTIBODY CAPTURE EIA**
Serum, plasma and synovial fluid specimens are tested by Lyme antibody capture (IgM, IgA and IgG) EIA for detection of antibodies to B. burgdorferi.

**BORRELIA MIYAMOTOI ANTIBODY ANALYSIS**
Serum or plasma specimens are tested for IgM and IgG antibodies to B. miyamotoi by indirect ELISA utilizing proprietary recombinant fusion-product antigens.

**BABESIA MICROTI ANTIBODY ANALYSIS**
Serum or plasma specimens are tested for IgG antibodies to B. microti by indirect immunofluorescence (IFA) and IgM and IgG antibodies to native B. microti proteins by Western blots.

**ANAPLASMA PHAGOCYTOPHILUM ANTIBODY ANALYSIS**
Serum or plasma specimens are tested for IgG antibodies to A. phagocytophilum by indirect ELISA utilizing proprietary recombinant fusion-product antigens.

**EHRlichia Chaffeensis ANTIBODY ANALYSIS**
Serum or plasma specimens are tested for IgG antibodies to E. chaffeensis by indirect immunofluorescence (IFA).

**TULAREMIA ANTIBODY ANALYSIS (FRANCISELLA TULARENSIS)**
Serum or plasma specimens are tested for antibodies (polyvalent) to F. tularensis by microagglutination.

**RICKETTSIA ANTIBODY ANALYSIS**
Serum specimens are tested for IgM and IgG antibodies to Spotted Fever and Typhus Fever group Rickettsia by indirect immunofluorescence (IFA).

**Note:** Some tests may not be orderable in every state. Contact info@oxfordimmunotec.com or call 1-877-598-2522 for test availability.

* Borrelia burgdorferi strains G39/40 and 49736

**CONTACT OXFORD IMMUNOTEC:**
Phone: 1-877-598-2522
Email: info@oxfordimmunotec.com
Web: www.oxfordimmunotec.com

**RESULTS AVAILABLE 24-48 HOURS AFTER RECEIPT OF SPECIMEN**
TICK-BORNE INFECTION ANALYSIS:
Regional offerings reflect disease epidemiology

EDTA WHOLE BLOOD ONLY

**Accutix™ Coastal Northeast/Upper Mid-West**
- Borrelia Species PCR†
  - B. miyamotoi
  - B. burgdorferi (Lyme)
- Babesia microti PCR
- Anaplasma phagocytophilum PCR
- Ehrlichia chaffeensis PCR
- Antibody capture (IgM, IgA and IgG) EIA for detection of antibodies to B. burgdorferi

**Accutix Upper Northeast**
- Borrelia Species PCR†
  - B. miyamotoi
  - B. burgdorferi (Lyme)
- Babesia microti PCR
- Anaplasma phagocytophilum PCR
- Antibody capture (IgM, IgA and IgG) EIA for detection of antibodies to B. burgdorferi

**Accutix Southeast**
- Borrelia Species PCR†
  - B. miyamotoi
  - B. burgdorferi (Lyme)
- Ehrlichia chaffeensis PCR
- Antibody capture (IgM, IgA and IgG) EIA for detection of antibodies to B. burgdorferi

**Accutix Coastal Northeast/Upper Mid-West PCR Screen**
- Borrelia Species PCR†
  - B. miyamotoi
  - B. burgdorferi (Lyme)
- Babesia microti PCR
- Anaplasma phagocytophilum PCR
- Ehrlichia chaffeensis PCR

**Accutix Upper Northeast PCR Screen**
- Borrelia Species PCR†
  - B. miyamotoi
  - B. burgdorferi (Lyme)
- Babesia microti PCR
- Anaplasma phagocytophilum PCR

**Accutix Southeast PCR Screen**
- Borrelia Species PCR†
  - B. miyamotoi
  - B. burgdorferi (Lyme)
- Ehrlichia chaffeensis PCR

† If Borrelia species DNA is detected, then PCR for the identification of B. miyamotoi and B. burgdorferi DNA is performed

PCR is performed pursuant to an agreement with Roche Molecular Systems, Inc.
Imugen is a division of Oxford Immunotec, Inc.
Accutix and the Accutix logo are trademarks of Oxford Immunotec Ltd.
The Oxford Immunotec logo is a registered trademark of Oxford Immunotec Ltd.
© 2018 Oxford Immunotec. All Rights Reserved.
MKT-DOC-3 V8.0

Imugen is Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited to perform high complexity clinical laboratory testing.

It is the laboratory’s policy to ensure providers are able to order only those tests that are medically necessary for the individual patient and to ensure the convenience of ordering a comprehensive analysis does not impact a provider’s ability to order only medically necessary testing. While the value of this convenience is recognized, indiscriminate use of comprehensive analyses may result in the ordering of tests that are not medically necessary. Therefore, all tests included in a comprehensive analysis can be ordered individually. If a component test is not listed individually on the requisition form, it may be written in the “Other Accutix Tests” field. Providers are encouraged to order individual tests when all of the tests included in a comprehensive analysis are not medically necessary for the individual patient.